Company intelligence / Profile preview

Leap Therapeutics, Inc.

Cambridge, Massachusetts, United Statesleaptx.com ↗

Ownership: Public · LPTX
Employees: ~100
Development stage: Phase 2

Overview

Leap's lead candidate sirexatamab (DKN-01) has shown promising results in Phase 2 trials, including a 32% higher overall response rate and 3.5 month longer progression-free survival in colorectal cancer patients with high DKK1 levels. The company has completed enrollment in the expanded Part B of the DeFianCe study for colorectal cancer and is continuing patient follow-up in the DisTinGuish study for gastroesophageal cancer.

Therapeutic areas: Oncology
Modalities: Monoclonal antibodiesBispecific antibodies
Industry: Biotech

Drug pipeline

9 assets

CureXcell

8 more assets in the full pipeline.

Request access →

Financials

Market cap: $31.9M
Total revenue: $0
Enterprise value: $24.3M

Beyond the preview

Go deeper on Leap Therapeutics, Inc..

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Leap Therapeutics, Inc..

Explore the full profile